Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency

Subcutaneous human IgG (SCIG) therapy in primary immunodeficiency (PID) offers sustained IgG levels throughout the dosing cycle and fewer adverse events (AEs) compared to intravenous immunoglobulin (IVIG). A phase I study showed good local tolerability of IgPro20, a new 20% liquid SCIG stabilized wi...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Hagan, John B., Fasano, Mary B., Spector, Sheldon, Wasserman, Richard L., Melamed, Isaac, Rojavin, Mikhail A., Zenker, Othmar, Orange, Jordan S.
Format: Artigo
Langue:Inglês
Publié: Springer US 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2935975/
https://ncbi.nlm.nih.gov/pubmed/20454851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-010-9423-4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires